Syme Rachel, Carleton Bruce, Leyens Lada, Richer Etienne
CIHR Institute of Cancer Research, Calgary, Alta., Canada.
Public Health Genomics. 2015;18(6):372-80. doi: 10.1159/000441560. Epub 2015 Nov 14.
There is currently a rapid evolution of clinical practices based on the introduction of patient stratification and molecular diagnosis that is likely to improve health outcomes. Building on a strong research base, complemented by strong support from clinicians and health authorities, the oncology field is at the forefront of this evolution. Yet, clinical research is still facing many challenges that need to be addressed in order to conduct necessary studies and effectively translate medical breakthroughs based on personalized medicine into standards of care. Leveraging its universal health care system and on resources developed to support oncology clinical research, Canada is well positioned to join the international efforts deployed to address these challenges. Available resources include a broad range of structures and funding mechanisms, ranging from direct clinical trial support to post-marketing surveillance. Here, we propose a clinical model for the introduction of innovation for precision medicine in oncology that starts with patients' and clinicians' unmet needs to initiate a cycle of discovery, validation, translation and sustainability development.
目前,基于患者分层和分子诊断的引入,临床实践正在迅速发展,这可能会改善健康结果。肿瘤学领域在强大的研究基础之上,再加上临床医生和卫生当局的大力支持,处于这一发展的前沿。然而,临床研究仍面临许多挑战,为了开展必要的研究并有效地将基于个性化医疗的医学突破转化为护理标准,这些挑战需要得到解决。利用其全民医疗保健系统以及为支持肿瘤学临床研究而开发的资源,加拿大完全有能力参与为应对这些挑战而开展的国际努力。可用资源包括广泛的结构和资助机制,从直接的临床试验支持到上市后监测。在此,我们提出一种临床模式,用于在肿瘤学中引入精准医学创新,该模式从患者和临床医生未满足的需求出发,启动一个发现、验证、转化和可持续发展的循环。